Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.